On May 21, Galena Biopharma Inc (NASDAQ:GALE) a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that data from the Company’s Phase 1 study with GALE-301, or Folate Binding Protein, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 50th Annual Meeting. Galena Biopharma Inc (NASDAQ:GALE) weekly performance is 42.92%. On last trading day company shares ended up $3.13. Analysts mean target price for the company is $6.88. Galena Biopharma Inc (NASDAQ:GALE) distance from 50-day simple moving average (SMA50) is 37.12%.
On May 28, Zacks reaffirmed their neutral rating on shares of Geron Corporation (NASDAQ:GERN) in a research note issued to investors on Tuesday. The firm currently has a $2.25 price target on the stock. Geron Corporation (NASDAQ:GERN) shares advanced 9.81% in last trading session and ended the day on $2.35. Its return on assets is -38.30%. Geron Corporation (NASDAQ:GERN) quarterly performance is -46.59%.
Biotech company Receptos Inc. (NASDAQ:RCPT) jumped 35% after releasing the results of its Phase 2 study. The research showed its multiple sclerosis drug reduced brain lesion activity. The Phase 3 portion of the trial began in December 2013. Receptos Inc (NASDAQ:RCPT) shares moved up 36.78% in last trading session and was closed at $39.94, while trading in range of $38.74 – $40.94. Receptos Inc (NASDAQ:RCPT) year to date (YTD) performance is 37.77%.
O June 5, Celldex Therapeutics, Inc. (Nasdaq:CLDX) continuing higher from earlier gains in the week. On Monday, the company reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Varlilumab is an immunotherapy designed to enhance the body’s natural immune response by directly activating T cells that can specifically recognize and kill cancer cells. Preclinical data support the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Varlilumab will enter at least four combination studies in the second half of 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX) ended the last trading day at $17.26. Company weekly volatility is calculated as 9.58% and price to cash ratio as 5.62. Celldex Therapeutics, Inc. (NASDAQ:CLDX) showed a positive weekly performance of 30.56%.
On June 10, 2014, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent (VAND-0092), application number 13/751,011, covering the method of use of HETLIOZ (tasimelteon) to treat Non-24-Hour Sleep-Wake Disorder (Non-24). The allowed claims relate to the method of treatment as described in the HETLIOZ label that was approved by the U.S. Food and Drug Administration (FDA) and include claims directed to treatment of the totally blind population that has this disorder. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) weekly performance is 49.30%. On last trading day company shares ended up $14.96. Analysts mean target price for the company is $24.67. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) distance from 50-day simple moving average (SMA50) is 16.34%.